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ABSTRACT
Introduction: Status epilepticus (SE) is a life-
threatening neurological emergency. SE lasting longer
than 120 min and not responding to first-line and
second-line antiepileptic drugs is defined as ‘refractory’
(RCSE) and requires intensive care unit treatment.
There is currently neither evidence nor consensus to
guide either the optimal choice of therapy or
treatment goals for RCSE, which is generally treated
with coma induction using conventional anaesthetics
(high dose midazolam, thiopental and/or propofol).
Increasing evidence indicates that ketamine (KE), a
strong N-methyl-D-aspartate glutamate receptor
antagonist, may be effective in treating RCSE.
We hypothesised that intravenous KE is more
efficacious and safer than conventional anaesthetics in
treating RCSE.
Methods and analysis: A multicentre, randomised,
controlled, open-label, non-profit, sequentially
designed study will be conducted to assess the
efficacy of KE compared with conventional anaesthetics
in the treatment of RCSE in children. 10 Italian centres/
hospitals are involved in enrolling 57 patients aged
1 month to 18 years with RCSE. Primary outcome is
the resolution of SE up to 24 hours after withdrawal of
therapy and is updated for each patient treated
according to the sequential method.
Ethics and dissemination: The study received
ethical approval from the Tuscan Paediatric Ethics
Committee (12/2015). The results of this study will be
published in peer-reviewed journals and presented at
international conferences.
Trial registration number: NCT02431663; Pre-
results.
INTRODUCTION
Background and rationale
Status epilepticus (SE) is a life-threatening
neurological emergency traditionally defined
as ‘an acute epileptic condition characterised
by continuous seizures for at least 30
minutes, or by 30 minutes of intermittent sei-
zures without full recovery of consciousness
between seizures’.1 Convulsive SE is the most
common and harmful form. There is now
consensus, based on an improved under-
standing of the pathophysiology, that any
seizure lasting longer than 5 min should be
treated as SE.2
SE lasting longer than 120 min and not
responding to first-line (benzodiazepines)
and second-line (midazolam (MDZ) at high
Strengths and limitations of this study
▪ This is the first randomised controlled study
assessing the efficacy of third-line therapy in
RCSE in children.
▪ It employs a sequential model approach, which
allows efficacy to be demonstrated with a small
number of patients.
▪ It assesses the possibility of avoiding endo-
tracheal intubation in the treatment of RCSE.
▪ RCSE is a rare condition, which may result in a
longer than originally planned duration of study.
▪ Enrolment of patients already on high dosages of
midazolam could require intubation in some.
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dose, phenytoin and phenobarbital) antiepileptic drugs
(AEDs) is defined as ‘refractory’ and requires intensive
care unit (ICU) treatment.2 The term ‘super refractory’
defines SE that continues, or recurs, for 24 hours or
longer or recurs after withdrawal of the anaesthetic
therapy.3
Even with current best practices, neurological sequelae
occur in >50% of children with refractory convulsive SE
(RCSE).4 5 The mortality rate of RCSE ranges between
2.7% and 5.2%, and increases up to 5–8% when only
ICU admissions are taken into account.4 5
There is general consensus regarding the first-line and
second-line treatments of SE. Although the types of
drugs available are similar in different countries, algo-
rithms/protocols may differ among countries and even
among different institutions in the same country; there
is currently neither evidence nor consensus to guide
either the optimal choice of therapy or treatment goals
for RCSE.3 6–8 RCSE is generally treated with coma
induction using high-dose MDZ or conventional anaes-
thetics such as thiopental (TPS) or propofol (PR),6–8
which all require endotracheal intubation, a negative
prognostic factor of morbidity and mortality.9–11 All con-
ventional anaesthetics commonly used in RCSE act on
inhibitory-γ-aminobutyric acid (GABAA) receptors.
6–8
Experimental models suggest that, with continuing sei-
zures, GABAA receptors are internalised in clathrin-
coated vesicles, and excitatory N-methyl-d-aspartate
(NMDA) receptors are mobilised to the membrane.12 13
This receptor trafficking results in decreased inhibitory
control and increased excitation that may foster SE.12 13
Conventional anaesthetics will therefore be less active,
making higher doses necessary, which will in turn
enhance their adverse events, especially hypotension,
requiring vasopressor administration.11 In this scenario,
NMDA modulating molecules, such as ketamine (KE),
represent an attractive treatment alternative for SE.14
Increasing evidence indicates that KE, a strong NMDA
glutamate receptor antagonist, may be effective in treat-
ing RCSE.14 Owing to its sympathomimetic action, KE
has no cardiac depressant properties and does not cause
hypotension.15 KE use does not necessarily require
amine administration or mechanical ventilation. Its
administration, therefore, does not imply emergent
endotracheal intubation, a prognostic factor of increased
morbidity and mortality risk in critically ill adults and
children.9–11 Between 15% and 39% of emergent endo-
tracheal intubations in adults are associated with one or
more complications including severe hypoxaemia,
haemodynamic collapse and death.9 11 The complica-
tion rate is even higher in the paediatric population, in
which acute deterioration can occur rapidly as a result
of age-related differences in physiology, oxyhaemoglobin
dissociation, oxygen consumption and pulmonary
mechanics.10 Large doses of KE and rapid intravenous
boluses may cause hallucinations, which are less fre-
quent in children than in adults and can be reduced
with benzodiazepine premedication.15 Moreover, KE
exerts a neuroprotective action by preventing the trans-
duction of signals to destructive intracellular mechan-
isms through the blockade of NMDA receptors.15 16
The literature contains good evidence about efficacy
and safety of KE in the adult and paediatric RCSE popu-
lations.3 14 However, the heterogeneity of prior treat-
ments, timing of KE administration, and KE dosage and
duration make available information on seizure respon-
siveness difficult to interpret.
In November 2009, the Paediatric Neurology Unit at the
Meyer Children’s Hospital (Florence, Italy) adopted a
treatment protocol for RCSE including intravenous KE
infusion.17 As of January 2013, in order to avoid mechan-
ical ventilation, we have used KE (Ketamina, Molteni SpA,
Italy) before considering conventional anaesthetics.18
Our paediatric series17 18 shows that treatment with KE
in RCSE is effective and safe, and that its use could be
considered before TPS and PR, unless specific contraindi-
cations exist. Based on these encouraging results, we
designed a nationwide multicentre randomised sequential
trial that has been approved by the Italian Medicines
Agency and includes 10 paediatric hospitals (EudraCT
number 2013-004396-12; ClinicalTrial.gov identification
number: NCT02431663).
Objectives
We hypothesised that intravenous KE is more effective
and safer than conventional anaesthetics (high-dose
MDZ, TPS and/or PR) in treating RCSE.
Primary objective
To assess the efficacy of KE compared with conventional
anaesthetics in the treatment of RCSE in children.
Secondary objectives
To assess the short-time safety profile of KE compared
with conventional anaesthetics and, in particular, to
evaluate the possibility of administering KE, thus avoid-
ing mechanical ventilation.
METHODS AND ANALYSIS
Study design
KETASER01 is an Italian, multicentre, randomised, con-
trolled, open-label, sequentially designed non-profit
study (ClinicalTrials.gov identifier: NCT02431663)
involving 10 centres/hospitals.
Study setting
Patients will be enrolled and treated in the ICUs at 10
Italian hospitals: (1) Meyer Children’s Hospital, Florence;
(2) Bambino Gesù Children’s Hospital, IRCCS, Rome; (3)
Gemelli Hospital, Catholic University, Rome; (4)
University Hospital, Padua; (5) Ospedali Riuniti, Ancona;
(6) University Hospital, Verona; (7) Burlo Garofolo
Institute for Maternal and Child Health, IRCCS, Trieste;
(8) Regina Margherita Children’s Hospital, Turin; (9)
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Buzzi Children’s Hospital, ICP, Milan; (10) Sant’Orsola-
Malpighi University Hospital, Bologna.
Patients will be randomised to the intervention arm or
control arm with a computer-assisted system. Block ran-
domisation with fixed size blocks and age stratification
(<4, 5 to 10 and 11 to 18 years) will be used.
Eligibility criteria
Inclusion criteria
Patients are eligible if (1) they are aged 1 month to
18 years of age; (2) they present with SE refractory to
first-line (benzodiazepines by mouth or by rectum) and
second-line (phenytoin 20 mg/kg and/or phenobarbital
20 mg/kg and MDZ up to 6 µg/kg/min) AEDs; (3)
their parents provide written consent.
Exclusion criteria
Patients will be excluded if (1) they have a contraindica-
tion to the use of any of the drugs in the study protocol;
(2) they have a presumed or ascertained pregnancy
status; (3) they had already been enrolled in the
KETASER01 study for an antecedent RCSE episode.
Patients with RCSE unresponsive to first-line and
second-line drugs will be transferred from the neuro-
logical department to the ICU. They will be enrolled in
the study by the neurologist and anaesthesiologist in the
ICU, after assessing the eligibility criteria and obtaining
informed consent from their parents.
Interventions
The experimental arm: KE
KE is administered starting with an initial bolus
of 2–3 mg/kg followed by continuous infusion of 10
µg/kg/min, increasing the infusion rate by 5–10 µg/kg/
min every 10 min up to a maximum of 100 µg/kg/min,
with every increment being preceded by a bolus of
1–2 mg/kg. KE is always administered in association with
2–4 µg/kg/min MDZ. For patients treated with continu-
ous infusion of MDZ (second-line therapy) for <5 days,
the dosage of the benzodiazepine is reduced from 6 to
2 µg/kg/min, to prevent emergence reactions. For
patients treated with MDZ for 5 or more days, the dose
of the benzodiazepine is reduced from 6 to 3–4 µg/
kg/min to avoid seizure occurrence secondary to abrupt
benzodiazepine withdrawal and prevent emergence reac-
tions.19 Dosages above 4 µg/kg/min, although previ-
ously not efficacious, could interfere with the evaluation
of the effectiveness of KE.
In case of RCSE resolution, the effective dosage of KE
is continued for a minimum of 48 hours up to a
maximum of 7 days, based on the EEG features of a con-
tinuous recording analysed by a neurologist. In the case
of no response (persistence of SE at the maximum treat-
ment dose) or adverse events, the drug is discontinued
and treatment failure is declared. KE is discontinued
gradually by reducing the starting dose by 25% every
12 hours for infusion dosages between 50 and
100 µg/kg/min; withdrawal may be more rapid (25% of
the starting dose every 6 hours) for dosages <50 µg/kg/
min or a shorter duration of infusion (48 hours; see
figure 1).
The control arm: MDZ and (TPS and/or PR)
The administration of conventional anaesthetics for the
treatment of RCSE follows the current guidelines that
consider MDZ at anaesthetic dosage as the first thera-
peutic option, followed by PR and/or TPS. The decision
to administer PR or TPS first is at the clinician’s
discretion.
MDZ is administered as follows: using increasing doses
of MDZ up to a maximum of 12 µg/kg/min, the dosage
is increased by 2 µg/kg/min every 5 min, with every
increment being preceded by a bolus of 0.15 mg/kg. In
the case of RCSE resolution, the effective dosage of
MDZ is continued for 48 hours. In the case of no
response (persistence of SE at the maximum treatment
dose) or adverse events, MDZ is discontinued and treat-
ment is continued with PR or TPS.
During the weaning process, MDZ is decreased by
1 µg/kg/min every 15 min if the infusion duration was
<72 hours; otherwise, weaning is to be performed more
slowly. In fact, studies conducted on weaning from BDZ
showed a higher incidence of tolerance and, therefore, of
abstinence, in patients who received higher doses and for
a longer period (≥3 days).19 We recommend a reduction
of 10–15% of the initial infusion dose every 6–8 hours
in patients receiving infusions for short periods (<3 to
5 days), and a reduction of 10–20% per day in patients
receiving infusions for longer periods (>5 to 7 days).
TPS is administered as follows: an initial bolus of
1–2 mg/kg, increasing the speed of continuous infusion
by 1 mg/kg/hour every 30 min, always preceding with a
bolus of 2 mg/kg, up to a maximum dosage of
6 mg/kg/hour. In the case of RCSE resolution, the
effective dosage of TPS is continued for 48 hours. In the
case of no response (persistence of SE at the maximum
treatment dose) or adverse events, the drug is discontin-
ued and treatment is continued with PR, if provided in
the hospital, or treatment failure is declared.
During the weaning process TPS is discontinued grad-
ually by reducing the starting dose by 25% every
3 hours. Phenobarbital therapy (5 mg/kg given twice) is
initiated during TPS reduction.
PR is administered as follows: an initial bolus of
1–2 mg/kg, increasing the speed of continuous infusion
by 1 mg/kg/hour every 5 min, always preceding with a
bolus of 1–2 mg/kg, up to a maximum dosage of 5 mg/
kg/hour. In the case of RCSE resolution, the effective
dosage of PR is continued for 48 hours. In the case of
no response (persistence of SE at the maximum treat-
ment dose) or adverse events, the drug is discontinued
and treatment failure is declared.
During the weaning process PR is gradually discontin-
ued by reducing the initial dose by 10% every 12 hours if
the maximal dose of 5 mg/kg/h has been reached and
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administered for 48 hours; withdrawal may be more rapid
for smaller doses or infusion durations (see figure 1).
Relevant concomitant care and interventions
The antiepileptic therapy is administered simultaneously
with the study drugs and the choice of AED is at the dis-
cretion of the clinician. Supportive therapy (eg, amine),
when necessary, is allowed (see table 1).20 21
Sample size
A sample size of 57 patients was estimated assuming
80% power, an α error of 5%, a percentage of success in
the experimental arm of 85% and a percentage of
success in the control arm of 60%. The study adopts a
sequential design with a non-truncated triangular test.22
Outcomes
Primary outcome
The control of SE up to 24 hours after the withdrawal of
therapy is defined by the following EEG features: (1)
appearance of suppression-burst pattern and/or; (2)
appearance of widespread β activity and/or (3) appear-
ance of slow activity in the absence of widespread or
lateralised, continuous or subcontinuous, and periodic
abnormalities (periodic lateralised epileptiform dis-
charges, eg).
Definition of treatment success
No recurrence of SE from the highest dose of the study
drugs until the 24th hour after withdrawal of the therapy.
Definition of treatment failure
The study treatments (control arm and treatment arm)
end when a therapeutic failure is declared, namely:
▸ Therapy completely failed to control SE;
▸ Recurrence of SE while therapy was being tapered or
within 24 hours of its withdrawal;
▸ Withdrawal of the study drug due to adverse events
defined according to the Common Toxicity Criteria
for Adverse Events (CTCAE);23
▸ Death during treatment with the study drugs or
within 24 hours after their withdrawal.
Secondary outcomes
1. Number of patients requiring mechanical ventila-
tion during treatment with KE;
2. Frequency of seizures during treatment, from the
time at which the maximum dose of study drugs was
reached until outcome assessment;
3. Frequency of seizures from outcome assessment to
hospital discharge;
4. Number of patients requiring drugs for cardiovascu-
lar support (amines);
5. Number of patients who respond to alternative
therapy administered after a treatment failure in
their study arm;
Figure 1 Flow chart. MDZ, midazolam; KE, ketamine; PR, propofol; TPS, thiopental.
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6. Number of patients requiring treatment withdrawal
due to adverse events;
7. Mortality rate;
8. Duration of mechanical ventilation;
9. Duration of stay in the ICU;
10. Total length of hospital stay.
Data collection methods
An electronic case report form (eCRF) with security
input rules has been developed in order to ensure
accurate data collection. Personal data are made
anonymous and codified by the system. Demographic,
clinical and anamnestic data are recorded at the time of
enrolment and throughout follow-up. Laboratory tests
and continuous EEG recordings are included in the
patient file. The final efficacy outcome is recorded in
each eCRF for the sequential analysis. All adverse events
are collected in the ‘adverse event’ section of the eCRF.
Serious adverse events are also immediately reported to
the European Medicines Agency (EudraVigilance).
Statistical methods
As the trial follows a randomised controlled sequential
model, the assessment of efficacy is updated after each
patient concludes treatment.22 Sequential methods com-
prise a commonly used frequentist approach to control
inflation of the false-positive error rate generated by mul-
tiple tests. This method of analysis regards only the
primary outcome and has the advantage of allowing early
discontinuation of the study in case of clear superiority of
the intervention arm or clear futility of the treatment. The
sequential analysis model allows early termination of the
trial in case of large differences between the two groups in
terms of efficacy. Secondary outcomes are reported in a
descriptive analysis as proportions, averages and medians.
Data monitoring
The coordinating centre (Meyer Children’s Hospital,
Florence) oversees the activity of the participating sites
through regular visits. The coordinating centre itself is
supported by the local internal Clinical Trial Office for
internal audits.
ETHICS AND DISSEMINATION
The study was approved by the Tuscan Paediatric Ethics
Committee, on 21 October 2014, and was registered on
the site ClinicalTrial.gov (number: NCT02431663). Any
amendment will be submitted to the local Ethics
Table 1 Table timeline
Pre-enrolment Enrolment Allocation T1
T2
0–48 hours
48 hours
to 7 days
Enrolment
Treatment failure to first-line and second-line
antiepileptic drugs
X
Eligibility assessment X
Administration PIM III20 and STESS21 X
Informed consent X
Allocation X
Interventions
Administration of MDZ/TPS/PR or KE up to a
maximum or up to SE resolution
X
Administration of maximum dosage of MDZ/TPS/PR up
to reduction-withdrawal
X
Administration of maximum dosage of KE up to
reduction-withdrawal
X X
Evaluation
Type and blood dosage of antiepileptic drugs in
progress
X X
Aetiological classification X X
Control of RSE X X X
Need for mechanical ventilation X X X
Frequency of seizures from outcome assessment to
hospital discharge
X X
Adverse events X X X
Tolerability X X X
Other variables (laboratory investigations,
monitoring video-EEG, monitoring cardiorespiratory
parameters, etc)
X X X
KE, ketamine; MDZ, midazolam; PIM, Paediatric Index of Mortality; PR, propofol; RSE, Refractory Status Epilepticus; STRESS, Status
Epilepticus Severity Score; TPS, thiopental.
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Committee. Signed informed consent is required from
both parents (see online supplementary file). We will
disseminate the results of our study via presentations at
international conferences and publications in peer-
reviewed journals.
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